Physician profile
Mark Lowry
NPI 1578569083
$1,844.87
in general payments reported to CMS, 2019-2025
24 companies · $347 in 2025
The $347 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $31.12 · 2021: $259 · 2022: $474 · 2023: $223 · 2024: $317 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $429.31 | 2021-2025 | Azstarys |
| Glaxosmithkline, LLC. | $313.49 | 2019-2024 | Bexsero, Pediarix, Rotarix |
| Ironshore Pharmaceuticals INC. | $186.91 | 2019-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $126.15 | 2021-2025 | Elaprase |
| Pfizer INC. | $104.00 | 2022-2025 | |
| Sanofi Pasteur INC. | $90.85 | 2019-2025 | |
| Ultragenyx Pharmaceutical INC. | $83.54 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $81.78 | 2024-2025 | Ycanth |
| Cranial Technologies, INC | $76.73 | 2019-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $47.81 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $38.72 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $36.53 | 2024 | |
| Biogen, INC. | $25.75 | 2022 | |
| Shire North American Group INC | $25.20 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $24.66 | 2023 | Flumist Quadrivalent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $23.20 | 2025 | Natroba, Spinosad |
| Tris Pharma INC | $22.99 | 2024 | Dyanavel Xr |
| Lnhc, INC | $21.66 | 2025 | Zelsuvmi |
| Rhythm Pharmaceuticals, INC. | $17.19 | 2022 | |
| Phadia US INC. | $16.42 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.71 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.28 | 2024 | |
| Mission Pharmacal Company | $11.65 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lowry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.